Alemtuzumab is named as an intervention in 3 current clinical trials in our USA register. 2 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Cellectis S.A (2). The most-studied condition is B-cell Non-Hodgkin Lymphoma (B-NHL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
NCT04150497 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | Cellectis S.A. | USA |
|
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
NCT05607420 · B-cell Non-Hodgkin Lymphoma (B-NHL)
|
Phase 1/2 | Recruiting | Cellectis S.A. | USA |
|
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
NCT05688436 · ClinicalTrials.gov ↗ · Multiple Sclerosis
|
Observational | Active, closed | Biogen | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Cellectis S.A. | 2 |
| Biogen | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA register name Alemtuzumab (also registered as CLLS52) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Cellectis S.A (2) and Biogen (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Alemtuzumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Alemtuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Alemtuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.